hPV19 + 5-fluorouracil + irinotecan + leucovorin

This is a **combination therapy** consisting of four agents: **hPV19** (a monoclonal antibody, presumably under clinical development, targeting an unspecified cancer antigen), **5-fluorouracil (5-FU)** (a cytotoxic antimetabolite interfering with DNA synthesis), **irinotecan** (a topoisomerase I inhibitor causing DNA damage and cell death), and **leucovorin** (also known as folinic acid, a folate analog used to enhance the efficacy and reduce toxicity of 5-FU). The combination is investigational; while 5-FU, irinotecan, and leucovorin are standard components of regimens for metastatic colorectal cancer and work synergistically to inhibit DNA synthesis and repair, hPV19 is presumed to add an additional mechanism, likely immunological or targeted, but details are not found in current literature. This regimen may be explored for its combined antiproliferative, DNA-damaging, and potentially immunomodulatory or targeting effects in solid tumors, most likely colorectal cancer.